Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,201–6,300 of 15,747
Zhu, F., Ma, S., Wen, H., Rao, M., Zhang, P., Peng, W., Cui, Y., Yang, H., Tan, C., Chen, J., et al. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2154846 · Cited by 16
“Particularly, the mRNA vaccine has already been utilized in protecting against influenza and Zika (Bahl et al., 2017; Richner et al., 2017), and recently, this technology has also been applied in combating the pandemic of COVID19 (Polack et al., 2020).”
MethodThe neighborhood built environment and COVID-19 hospitalizations
Rigolon, A., Németh, J., Anderson-Gregson, B., Miller, A. R., deSouza, P., Montague, B. T., Hussain, C., Erlandson, K. M., & Rowan, S. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286119 · Cited by 14
van der Toorn, W., Oh, D., & von Kleist, M. (2021) · Patterns · doi:10.1016/j.patter.2021.100264 · Cited by 15
From Emergence to Endemicity: A Comprehensive Review of COVID-19
Naik, R., Avula, S., Palleti, S. K., Gummadi, J., Ramachandran, R., Chandramohan, D., Dhillon, G. S., Gill, A. S., Paiwal, K., Shaik, B. F., et al. (2023) · Cureus · doi:10.7759/cureus.48046 · Cited by 21
The Immunopathobiology of SARS-CoV-2 Infection
Patel, M., Shahjin, F., Cohen, J. D., Hasan, M., Machhi, J., Chugh, H., Singh, S., Das, S., Kulkarni, T. A., Herskovitz, J., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab035 · Cited by 15
Janssen, C., Cachanado, M., Ninove, L., Lachâtre, M., Michon, J., Épaulard, O., Maakaroun-Vermesse, Z., Chidiac, C., Laviolle, B., Aumaître, H., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101444 · Cited by 18
Site-specific steric control of SARS-CoV-2 spike glycosylationPreprint
Allen, J. D., Chawla, H., Samsudin, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.08.433764 · Cited by 13
Lei, Q., Yu, C., Li, Y., Hou, H., Xu, Z., Yao, Z., Zhang, Y., Lai, D., Ndzouboukou, J. B., Zhang, B., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.014 · Cited by 13
Peng, D., Zhao, T., Hong, W., Fu, M., He, C., Chen, L., Ren, W., Hong, L., Yang, J., Alu, A., et al. (2023) · MedComm · doi:10.1002/mco2.238 · Cited by 13
Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology
Ochola, L. B., Ogongo, P., Mbugua, S. M., Gitaka, J., & Suliman, S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.005 · Cited by 14
“S(119) from Johnson and Johnson, or more specifically the RBD of BTN162b2 by Pfizer-BioNTech.(120) Therefore, in populations that receive Spike-based vaccines, LFAs targeting the N and S antigens can be”
BackgroundCorma‐Gómez, A., Fernández‐Fuertes, M., Viñuela, L., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28602 · Cited by 13
Fardanesh, R., Thakur, S. B., Sevilimedu, V., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.795265 · Cited by 13
“It may be caused by various benign conditions (1, 2) or more recently after COVID-19 vaccinations (3, 4); therefore, patients with a personal history or concurrent diagnosis of breast cancer in particular can pose a diagnostic dilemma.”
BackgroundDevelopment of a Modular NTA:His Tag Viral Vaccine for Co-delivery of Antigen and Adjuvant
Chung, Y. H., Volckaert, B. A., & Steinmetz, N. F. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00601 · Cited by 16
Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines
Gardner, J., Abrams, S. T., Toh, C., Parker, A. L., Lovatt, C., Nicolson, P. L. R., Watson, S. P., Grice, S., Hering, L. M., Pirmohamed, M., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00895-z · Cited by 13
Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs
Garcia-Guerra, A., Sathyaprakash, C., de Jong, O. G., Lim, W. F., Vader, P., Andaloussi, S. E., Bath, J., Reiné, J., Aoki, Y., Turberfield, A. J., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf016 · Cited by 15
“This provides flexibility to use a wide range of carriers, from adeno-associated viruses 57 , which require in situ transcription of the sgRNA, to lipid nanoparticles 47,48 , which require chemically synthesized sgRNAs 58 .”
van Ewijk, C. E., Kooijman, M. N., Fanoy, E. B., Raven, S. F. H., Middeldorp, M., Shah, A. A., de Gier, B., de Melker, H. E., Hahné, S. J. M., & Knol, M. J. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.45.2200217 · Cited by 15
COVID19 Vaccination in Frail People. Lots of Hope and Some Questions
Rolland, Y., Cesari, M., Morley, J. E., Merchant, R. A., & Vellas, B. J. (2021) · The journal of nutrition health & aging · doi:10.1007/s12603-021-1591-9 · Cited by 14
Wichaidit, M., Nopsopon, T., Sunan, K., Phutrakool, P., Ruchikachorn, P., Wanvarie, D., Pratanwanich, P. N., Cheewaruangroj, N., Punyabukkana, P., & Pongpirul, K. (2022) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2022.100106 · Cited by 14
Warkentin, L., Zeschick, N., Kühlein, T., Steininger, P. A., Überla, K., Kaiser, I., Gall, C. M., Sebastião, M., & Hueber, S. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-022-07443-x · Cited by 13
“Therefore, results are also reported separately for gender and age with a threshold of 55 years chosen according to other studies on COVID19 vaccines [1, 2, 16].”
ResultChan, E. W. W., Leung, M. T. Y., Lau, L. K. W., Leung, J. C. N., Lum, D. H., Wong, R. S. M., Li, X., Chui, C. S. L., Wan, E. Y. F., Wong, C. K. H., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.12.354 · Cited by 13
Pulmonary fibrosis and COVID-19
Kramer, D., Hilton, R., & Roman, J. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.07.006 · Cited by 15
Gonzalez, M. A., Bhatti, A., Fitzpatrick, K. S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008338 · Cited by 13
Wilkinson, T. M. A., Soyza, A. D., Carroll, M. W., Chalmers, J. D., Crooks, M. G., Griffiths, G. O., Shankar‐Hari, M., Ho, L., Horsley, A. R., Kell, C., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00249-2023 · Cited by 15
Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants
Kim, Y. C., Kim, B., Son, N., Heo, N., Nam, Y., Shin, A., Yang, A. J., Kim, M. H., Kyong, T., Kang, E., et al. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e9 · Cited by 14
Hypersensitivity Reactions to Vaccines: Current Evidence and Standards for SARS-CoV-2 Vaccines
Carvalho, J. C., Cunha, F., Coutinho, I. A., Loureiro, C., Faria, E., & Todo‐Bom, A. M. (2021) · Acta Médica Portuguesa · doi:10.20344/amp.16096 · Cited by 13
Müller‐Hilke, B., Mai, F., Müller, M. K., Volzke, J., & Reisinger, E. C. (2022) · Vaccines · doi:10.3390/vaccines10020322 · Cited by 12
“Both vaccines were shown to be safe and were 95% (BNT162b2) and up to 90% (AZD1222) efficacious against symptomatic COVID-19 when analyzed more than 14 days after the second dose [5,6].”
BackgroundLi, X., Wang, H., Lai, W., Liao, J., Mo, W., Huang, K., He, L., Liang, X., Yu, Z., Xu, J., et al. (2024) · Immunology · doi:10.1111/imm.13777 · Cited by 14
“The successful uses of mRNA-based vaccine to prevent COVID-19 has demonstrated the safety and efficacy of this vaccine platform [9].”
Rouatbi, N., Walters, A. A., Zam, A., Lim, Y. M., Marrocu, A., Liam‐Or, R., Anstee, J. E., Arnold, J. N., Wang, J. T.-W., Pollard, S. M., et al. (2025) · Advanced Science · doi:10.1002/advs.202407262 · Cited by 17
Lim, X. Y., Chan, J. S. W., Tan, T. Y. C., Teh, B. P., Razak, M. R. M. A., Mohamad, S. B., & Mohamed, A. F. S. (2021) · Natural Product Communications · doi:10.1177/1934578x211016610 · Cited by 14
Shimizu, T., Kawaguchi, Y., Ando, H., Ishima, Y., & Ishida, T. (2022) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00047 · Cited by 13
Colmegna, I., Valerio, V., Amiable, N., Useche, M., Rampakakis, E., Flamand, L., Rollet, E., Bessette, L., Fitzcharles, M., Hazel, E., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2023-003400 · Cited by 24
Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine
Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12010057 · Cited by 13
“most frequently reported adverse actions [60,61,95].”
BackgroundLeveraging learner‐centered educational frameworks to combat health mis/disinformation
Sheng, A. Y., Gottlieb, M. A., & Welsh, L. A. (2021) · AEM Education and Training · doi:10.1002/aet2.10711 · Cited by 13
Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
Oka, A., Sudo, Y., Miyoshi, T., Ozaki, M., Kimura, Y., Takagi, W., Ugawa, S., Okada, T., Nosaka, K., & Doi, M. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5378 · Cited by 11
SARS-CoV-2 Infection and Vaccination Outcomes in Multiple Sclerosis
Brunn, J. A., Dunietz, G. L., Romeo, A. R., & Braley, T. J. (2022) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001164 · Cited by 13
“On submission of this paper, 2 studies have been published on SARS-CoV-2 vaccination in PwMS.14,15 Data from Achiron et al. studied the Pfizer-BioNTech vaccination in PwMS at Sheba Medical Center in Israel.”
BackgroundInfluentialHaddaden, M., Aldabain, L., Patel, N., Maharaj, A., Saif, A., Imam, Z., & Haas, C. J. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1951943 · Cited by 12
“The side effects reported by HCWs in our hospitals are comparable to side effects reported by Polack FP et al with few differences[9], irrespective of Table 1.”
ResultAntiviral nanopharmaceuticals: Engineered surface interactions and virus‐selective activity
Kolanthai, E., Neal, C. J., Kumar, U., Fu, Y., & Seal, S. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1823 · Cited by 14
Wong, B., & Mabbott, N. A. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltae011 · Cited by 22
Return to normal: COVID-19 vaccination under mitigation measures
Marziano, V., Guzzetta, G., Mammone, A., et al. (2021) · medRxiv · doi:10.1101/2021.03.19.21253893 · Cited by 5
Zhu, J., Xu, L., Wang, W., Xiao, M., Li, J., Wang, L., & Jiang, X. (2024) · ACS Omega · doi:10.1021/acsomega.4c03526 · Cited by 13
Desai, A., Deepak, P., Cross, R. K., Murone, J., Farraye, F. A., Ungaro, R. C., & Kochhar, G. S. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac252 · Cited by 13
Semenzato, L., Botton, J., Baricault, B., Deloumeaux, J., Joachim, C., Sylvestre, E., Dray-Spira, R., Weill, A., & Zureik, M. (2022) · PLOS ONE · doi:10.1371/journal.pone.0274309 · Cited by 13
Ouattara, E. N., Bruandet, A., Borde, A., Lenne, X., Binder-Foucard, F., Bourhis-Zaimi, M. L., Muller, J., Loc, P. T. B., Séguret, F., du Montcel, S. T., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001002 · Cited by 13
Camel nanobodies broadly neutralize SARS-CoV-2 variants
(2021) · doi:10.1101/2021.10.27.465996 · Cited by 13
“Most vaccines, including those mRNA-based, are designed to induce immunity against the spike or RBD (10-14).”
Bennett, C., Rivers, E. J., Woo, W., Bloch, M., Cheung, K., Griffin, P., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad508 · Cited by 15
“High vaccine efficacy against the ancestral (Wuhan) strain of SARS-CoV-2 was reported for BNT162b2 (Pfizer/BioNTech, July 2020–November 2020) [3], mRNA-1273 (Moderna, July 2020–October 2020) [4], the UK-based trial of the Matrix-M–adjuvanted recombinant spike (rS) protein COVID-19 vaccine…”
BackgroundAmmirati, E., Cavalotti, C., Milazzo, A., Pedrotti, P., Soriano, F. S., Schroeder, J. W., Morici, N., Giannattasio, C., Frigerio, M., Metra, M., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100778 · Cited by 15
Retracted(2022) · doi:10.1101/2022.01.18.22269452 · Cited by 380
Impfempfehlungen der Ständigen Impfkommission (STIKO)
Bogdan, C. (2021) · Der Hautarzt · doi:10.1007/s00105-021-04761-0 · Cited by 14
Cugno, M., Consonni, D., Lombardi, A., Bono, P., Oggioni, M., Renteria, S. U., Pesatori, A. C., Castaldi, S., Riboldi, L., Bordini, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9091011 · Cited by 12
“After vaccination with the BNT162b2 mRNA COVID-19 vaccine, the main adverse events are short-term, mild-to-moderate pain at the injection site, fatigue, and headache [1].”
BackgroundBayesian Statistics for Medical Devices: Progress Since 2010
Campbell, G., Irony, T., Pennello, G. A., & Thompson, L. (2023) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00495-w · Cited by 16
A potential silver lining of delaying the second dose
Martinez, D. R., & Ooi, E. E. (2022) · Nature Immunology · doi:10.1038/s41590-022-01143-z · Cited by 12
Mamaghani, S., Penna, R. R., Frei, J., Wyss, C., Mellett, M., Look, T., Weiß, T., Guenova, E., Kündig, T. M., Läuchli, S., et al. (2024) · Cells · doi:10.3390/cells13151242 · Cited by 17
“…proved to be an advantageous and versatile vaccination tool, whether modified (Spikevax ® from Moderna [13] and Comirnaty ® from BioNTech/Pfizer [11]) or unmodified (CVcoV ® [32–35], efficacious but not marketed, approved ARCT-154 ® [36] from Arcturus), numerous vaccines against pathogens,…”
BackgroundInsights into SARS-CoV-2-associated subacute thyroiditis: from infection to vaccine
Ziaka, M., & Exadaktylos, A. K. (2023) · Virology Journal · doi:10.1186/s12985-023-02103-1 · Cited by 15
“The most frequently observed side effect refers to mild reactions, including pain and swelling at the injection site, fever, headaches, chills, muscle/ joint aches, and tiredness [24].”
BackgroundFulminant myocarditis following coronavirus disease 2019 vaccination: a case report
Agdamag, A. C., Gonzalez, D., Carlson, K., Konety, S., McDonald, W. C., Martin, C. M., Maharaj, V., & Alexy, T. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytac007 · Cited by 15
Khan, M., Musazzi, U. M., Manellari, S., Mouawad, N., Damiano, G., Rinaldi, R., Raucci, A., Costantino, S., Paneni, F., Minghetti, P., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107847 · Cited by 17
Weigert, A. L. L., Bergman, M., Gonçalves, L. A., Godinho, I., Duarte, N., Abrantes, R., Borges, P., Brennand, A., Malheiro, V., Matoso, P., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.796676 · Cited by 15
Stati, G., Amerio, P., Nubile, M., Sancilio, S., Rossi, F., & Pietro, R. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021404 · Cited by 15
“Around the world, the percentage of short-term adverse reactions has been shown to be limited in number [3], since only transient local, and systemic reactions in the short- and medium-term have been assessed [4].”
BackgroundAdverse events following administration of COVID-19 vaccines in Saudi Arabia
Alqahtani, S. A., Jokhdar, H., Al‐Tawfiq, J. A., Al-Otaibi, S. N., Assiri, A. M., Almudarra, S., Alabdulkareem, K. I., & Haji, A. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-23471-8 · Cited by 14
Epigenetic Mechanisms Underlying COVID-19 Pathogenesis
Kaneko, S., Takasawa, K., Asada, K., Shinkai, N., Bolatkan, A., Yamada, M., Takahashi, S., Machino, H., Kobayashi, K., Komatsu, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091142 · Cited by 13
“In particular, the results of a large placebo-controlled trial of vaccines from Pfizer and Moderna have shown that two repeated doses of the vaccine are highly effective in preventing COVID-19 (more than 90%) [10,11].”
BackgroundZahrádka, I., Petr, V., Módos, I., Magicová, M., Dušek, L., & Viklický, O. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2973 · Cited by 15
Marincu, I., Cîtu, C., Bratosin, F., Bogdan, I. G., Timircan, M. O., Gurban, C., Bota, A. V., Brăescu, L., & Grigoraş, M. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020259 · Cited by 14
“In less than one year, extremely effective vaccinations were released, and a global-scale vaccination campaign began [2].”
BackgroundGlampson, B., Brittain, J., Kaura, A., et al. (2021) · medRxiv · doi:10.1101/2021.04.08.21254580 · Cited by 13
“This finding is similar to phase three trial (3) data showing a benefit from day 10- 13 post a first dose in the Pfizer vaccine, and from day 18 in a real-world data study (16).”
BackgroundResultInfluentialNoninfectious Uveitis Risk After COVID-19 Vaccination: A Nationwide Retrospective Cohort Study
Chang, M. S., Kim, H. R., Kim, S., Lee, C. S., Byeon, S. H., Kim, S. S., Lee, S. W., & Kim, Y. J. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.09.015 · Cited by 12
Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination
Iwata, H., Kamiya, K., Kado, S., Nakaya, T., Kawata, H., Komine, M., & Ohtsuki, M. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.16167 · Cited by 15
Atypical Sites of Lymphadenopathy after Anti-COVID-19 Vaccine: Ultrasound Features
Cocco, G., Pizzi, A. D., Taraschi, A. L., et al. (2022) · Medicina · doi:10.3390/medicina58020197 · Cited by 13
“The progressive spread of SARS-CoV-2 all over the world, the related disease severity, and the impact on everyday life and economics have stimulated the development of vaccines with a high safety profile to limit the rising infection rates [5,6].”
BackgroundTauzin, A., Beaudoin-Bussières, G., Gong, S. Y., Chatterjee, D., Gendron‐Lepage, G., Bourassa, C., Goyette, G., Racine, N., Khrifi, Z., Turgeon, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104990 · Cited by 13
Global Trends in Ophthalmic Practices in Response to COVID-19
Tan, T., Chodosh, J., McLeod, S. D., Parke, D. W., Yeh, S., Wong, T. Y., & Ting, D. S. W. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.07.027 · Cited by 13
Calcific tendinitis of the shoulder induced by an mRNA vaccine for COVID-19: A case report
Nakajima, K., Miyata, A., Kato, S., et al. (2022) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxac006 · Cited by 13
“COVID-19 vaccines have been widely adopted and have proven efficacious in fighting this pandemic [2].”
BackgroundInfluentialReneer, Z. B., Bergeron, H. C., Reynolds, S., Thornhill-Wadolowski, E., Feng, L., Bugno, M., Truax, A. D., & Tripp, R. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297833 · Cited by 16
Brugada syndrome and COVID-19 vaccines
Caturano, A., Pafundi, P. C., Sasso, F. C., Dendramis, G., Brugada, P., & Russo, V. (2021) · EP Europace · doi:10.1093/europace/euab211 · Cited by 13
Efficacy and limitations of repurposed drugs and vaccines for COVID-19
Murmu, N., Sarkar, M., Dey, S., Manna, R., Roy, S., Mondal, T., Halder, S., Bhattacharjee, N., Dash, S. K., & Giri, B. (2023) · Journal of Medicine Surgery and Public Health · doi:10.1016/j.glmedi.2023.100041 · Cited by 13
Hüls, A., Feany, P. T., Zisman, S. I., Costa, A. C. S., Dierssen, M., Balogh, R. S., Bargagna, S., Baumer, N., Brandão, A. C., Carfì, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10040530 · Cited by 15
Polymyalgia Rheumatica Following COVID-19 Vaccination
Yokote, A., Fujioka, S., Takahashi, N., Mishima, T., & Tsuboi, Y. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8934-21 · Cited by 13
“Large clinical studies have shown that this vaccine is safe and effective in preventing infection (4).”
BackgroundShirata, M., Ito, I., Tanaka, M., Murata, K., Murakami, K., Ikeda, H., Oi, I., Hamao, N., Nishioka, K., Hayashi, Y., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01163-5 · Cited by 14
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
Belov, B. S., Lila, A. M., & Nasonov, E. L. (2022) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2022-21-31 · Cited by 14
Hederman, A. P., Natarajan, H., Heyndríckx, L., Ariën, K. K., Wiener, J. A., Wright, P. F., Bloch, E. M., Tobian, A. A. R., Redd, A. D., Blankson, J. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40960-0 · Cited by 19
Cabanillas-Bernal, O., Cervantes-Luévano, K., Flores-Acosta, G. I., Bernáldez-Sarabia, J., & Licea-Navarro, A. F. (2022) · Vaccines · doi:10.3390/vaccines10040629 · Cited by 17
“The Pfizer vaccine showed the highest efficacy in trials (95%), followed J&J (71–81%), and then CanSino (65%) [3,5,6].”
BackgroundThe future of genetic medicines delivered via targeted lipid nanoparticles to leukocytes
Tarab‐Ravski, D., Stotsky‐Oterin, L., Elisha, A., Kundoor, G. R., Ramishetti, S., Hazan‐Halevy, I., Haas, H., & Peer, D. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.014 · Cited by 13
Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
Jiang, H., Zou, X., Zeng, P., Zeng, X., Zhou, X., Wang, J., Zhang, J., & Li, J. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00134-2 · Cited by 16
Stebbings, R., Jones, C., Cotton, P., Armour, G., Maguire, S., Skellett, V., Tang, C.-M., Goodman, J., Brady, T. M., Takahashi, V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836492 · Cited by 12
Gorgui, J., Atallah, A., Boucoiran, I., Sandoval, Y.-H. G., Bérard, A., & and the CONCEPTION Study Group (2022) · CMAJ Open · doi:10.9778/cmajo.20210273 · Cited by 15
Liang, Y., Ma, L., Wang, Y., Zheng, J., Su, L., & Lyu, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1253799 · Cited by 16
Sablerolles, R. S. G., Goorhuis, A., GeurtsvanKessel, C. H., de Vries, R. D., Huckriede, A. L. W., Koopmans, M., Lafeber, M., Postma, D. F., van Baarle, D., Visser, L. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753319 · Cited by 12
“The CombiVacS (12) study shows that a second dose of BNT162b2 administered 8-12 weeks after a prime with ChAdOx1 nCoV-19 elicited a robust immune response.”
InfluentialAgallou, M., Koutsoni, O. S., Michail, M., Zisimopoulou, P., Tsitsilonis, O., & Karagouni, E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac421 · Cited by 13
Gordeychuk, I. V., Kozlovskaya, L. I., Siniugina, A. A., Владимировна, Я. Н., Kuzubov, V. I., Анатольевич, З. К., Volok, V. P., Dodina, M., Gmyl, L. V., Коротина, Н. А., et al. (2023) · Viruses · doi:10.3390/v15091828 · Cited by 14
“…than 6.9 million lives as of May 2023 [1] In order to ensure the availability of vaccines against COVID-19 to every country in the world, all existing vaccine platforms and manufacturing capacities were employed, including genetic [2,3], vector [4,5], subunit [6] and inactivated [7–10] vaccines.”
InfluentialAzamor, T., Horbach, I. S., Cunha, D. B. E., Melgaço, J. G., da Silva, A. M. V., Tubarão, L. N., Azevedo, A. D. S., Santos, R. T., Alves, N. D. S., Machado, T. L., et al. (2022) · Viruses · doi:10.3390/v14091916 · Cited by 14
Antiviral nanomedicine: Advantages, mechanisms and advanced therapies
Pu, Y., Zhu, C., Liao, J., Gong, L., Wu, Y., Liu, S., Wang, H., Zhang, Q., & Lin, Z. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.05.030 · Cited by 29
Butt, A. A., Talisa, V. B., Peng, Y., Shaikh, O. S., Omer, S. B., & Mayr, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac118 · Cited by 14
“Ac ce pte d M an us cri pt In randomized, placebo controlled clinical trials, mRNA vaccines developed by Pfizer (BNT-162b2) and Moderna (mRNA-1273) demonstrated 94%-95% efficacy against symptomatic infection and nearly 100% efficacy against severe disease or death.[1, 2] Subsequent effectiveness studies in the real-wo…”
BackgroundResultLiu, Y.-L., Liao, T.-Y., Ho, K., Liu, E.-S., Huang, B., Hong, S.-T., Hsieh, Y.-C., Chang, M.-S., Wu, B. G., Chen, F.-M., et al. (2024) · Biomaterials Research · doi:10.34133/bmr.0112 · Cited by 17
Gil-Manso, S., Alonso, R., Catalán, P., Sánchez-Arcilla, I., Marzola, M., Correa‐Rocha, R., Pion, M., Muñóz, P., & Gregorio Marañón Microbiology-ID COVID-19 Study Group (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1035155 · Cited by 14
“In the context of COVID-19, the two main vaccine candidates developed were the BNT162b2 (Pfizer/BioNTech) (Polack et al., 2020) and mRNA-1273 (Moderna) (Jackson et al.”
BackgroundMethodMehta, N., Shah, S., Paudel, K., Chamlagain, R., & Chhetri, S. (2022) · Health Science Reports · doi:10.1002/hsr2.700 · Cited by 12
“Patients on maintenance hemodialysis were not included in the crucial trial that demonstrated 95% protection against COVID‐19 infection after a two‐dose regimen of the BNT162b2 vaccination.(18) Although the clinically significant antibody concentration cut‐off value for definitive sero protection is unknown, hemodialy…”
BackgroundHow Are Natural-Based Polymers Shaping the Future of Cancer Immunotherapy—A Review
Rodrigues, D. B., Reis, R. L., & Pirraco, R. P. (2023) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2023.2234462 · Cited by 15
“This was clearly evidenced recently with the use of this technology to develop two of the first United States Food and Drug Administration (FDA) approved mRNA vaccines to deal with the COVID-19 pandemic, namely the vaccines developed by BioNTech 95 and Moderna.”
BackgroundZiv, A., Heshin‐Bekenstein, M., Haviv, R., Kivity, S., Netzer, D., Yaron, S., Schur, Y., Egert, T., Egert, Y., Sela, Y., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac408 · Cited by 16
Shinomiya, N., Minari, J., Yoshizawa, G., Dando, M., & Shang, L. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.966586 · Cited by 14
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.